Economic Impact of Hospitalizations in Us Adults With Sarcopenia

Goates, Scott; Du, Kristy; Arensberg, Mary Beth; Gaillard, Trudy; Guralnik, Jack M.; Pereira, Suzette L.

doi:10.14283/jfa.2019.10

Cited by 120 publications

(99 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…conducted an epidemiological survey on people aged 68–82 in Canada, which showed that the prevalence of sarcopenia was 38.9% in men and 17.8% in women. According to a survey in the USA in 2019, the total hospitalization cost of patients with sarcopenia was approximately 40.4 billion US dollars, which represents a huge economic burden on the health care system of the USA 12 . In addition, data from the UK 13 and the Czech Republic 14 also show that muscle weakness (including sarcopenia) can lead to an increase in direct medical costs.…”

Section: Introductionmentioning

confidence: 99%

Mouse models of sarcopenia: classification and evaluation

Xie

Dong-sheng

et al. 2021

J cachexia sarcopenia muscle

114

View full text Add to dashboard Cite

Sarcopenia is a progressive and widespread skeletal muscle disease that is related to an increased possibility of adverse consequences such as falls, fractures, physical disabilities and death, and its risk increases with age. With the deepening of the understanding of sarcopenia, the disease has become a major clinical disease of the elderly and a key challenge of healthy ageing. However, the exact molecular mechanism of this disease is still unclear, and the selection of treatment strategies and the evaluation of its effect are not the same. Most importantly, the early symptoms of this disease are not obvious and are easy to ignore. In addition, the clinical manifestations of each patient are not exactly the same, which makes it difficult to effectively study the progression of sarcopenia. Therefore, it is necessary to develop and use animal models to understand the pathophysiology of sarcopenia and develop therapeutic strategies. This paper reviews the mouse models that can be used in the study of sarcopenia, including ageing models, genetically engineered models, hindlimb suspension models, chemical induction models, denervation models, and immobilization models; analyses their advantages and disadvantages and application scope; and finally summarizes the evaluation of sarcopenia in mouse models.

show abstract

Section: Introductionmentioning

confidence: 99%

Mouse models of sarcopenia: classification and evaluation

Xie

Dong-sheng

et al. 2021

J cachexia sarcopenia muscle

114

View full text Add to dashboard Cite

show abstract

“…The analysis included data from 4011 subjects during the period from 1999 to 2004. The analysis showed that 15.1% of individuals had sarcopenia and those in that group had about twice the odds of hospitalization compared with individuals without sarcopenia [2]. Osteoporosis often develops "silently" with patients often not learning of their condition until a fracture occurs.…”

Section: Introductionmentioning

confidence: 99%

Applications of Lipidomics to Age-Related Musculoskeletal Disorders

O’Connell

2021

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of Review The goal of this review is to highlight the need for new biomarkers for the diagnosis and treatment of musculoskeletal disorders, especially osteoporosis and sarcopenia. These conditions are characterized by loss of bone and muscle mass, respectively, leading to functional deterioration and the development of disabilities. Advances in high-resolution lipidomics platforms are being used to help identify new lipid biomarkers for these diseases. Recent Findings It is now well established that bone and muscle have important endocrine functions, including the release of bioactive factors in response to mechanical and biochemical stimuli. Bioactive lipids are a prominent set of these factors and some of these lipids are directly related to the mass and function of bone and muscle. Recent lipidomics studies have shown significant dysregulation of lipids in aged muscle and bone, including alterations in diacylglycerols and ceramides. Studies have shown that alterations in some types of plasma lipids are associated with aging including reduced bone mineral density and the occurrence of osteoporosis. Summary Musculoskeletal disorders are a major burden in our society, especially for older adults. The development and application of new lipidomics methods is making significant advances in identifying new biomarkers for these diseases. These studies will not only lead to improved detection, but new mechanistic insights that could lead to new therapeutic targets and interventions.

show abstract

“…Based on our knowledge, the designed economic model in present study is the first full economic evaluation model to compare sarcopenia screening strategies, which due to all limitations of information, tried to be designed and implemented systematically and step by step based on the best available evidences. Previous studies have focused more on the clinical features of the sarcopenia and in some cases the economic costs of the disease, such as the study of Janssen et al (2004) and Goates et al (2019) in the US [33,52] and the study of Sousa et al (2016) in Portugal [53].…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran

et al. 2021

View full text Add to dashboard Cite

Background and objectives Sarcopenia is an important age-related disease which can lead to an increased risk of mortality, falls, fractures, and poor quality of life. So, timely detection can be effective in reducing the burden of disease. The aim of this study was to identify the most cost-effective strategy for sarcopenia screening in Iran. Materials and methods We constructed a Markov transition model over a life-time horizon based on natural history. Compared strategies included Sarcopenia scoring assessment models (SarSA-Mod), European working group on sarcopenia in older people (EWGSOP), Mini sarcopenia risk assessment (MSRA) and SARC-F. Parameters values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Sensitivity analysis of uncertain parameters was also performed to determine the robustness of the model. Analysis was performed using 2020 version of TreeAge Pro software. Results All four screening strategies increased life time QALYs. After removing dominated strategy, the incremental cost per QALY gained for sarcopenia screening varied from $1875.67 for EWGSOP to $1898.33 for MSRA. Our base-case analysis showed that the most cost-effective strategy was EWGSOP and 2nd best was SarSA-Mod with $43,414.3 and $42,663.3 net monetary benefits given one GDP per capita ($5520.311) as willingness to pay, respectively. Sensitivity analysis of model parameters also showed robustness of results. Conclusions The results of the study, as the first economic evaluation of sarcopenia screening, showed that the EWGSOP strategy is more cost-effective than other strategies.

show abstract

Economic Impact of Hospitalizations in Us Adults With Sarcopenia

Cited by 120 publications

References 25 publications

Mouse models of sarcopenia: classification and evaluation

Mouse models of sarcopenia: classification and evaluation

Applications of Lipidomics to Age-Related Musculoskeletal Disorders

Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran

Contact Info

Product

Resources

About